Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases

PURPOSE: The CD40–CD40L pathway is a promising treatment target for autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus and lupus nephritis. The safety, pharmacokinetics and pharmacodynamics of BI 655064, a novel humanised antagonistic anti-CD40 monoclonal antibody, were i...

Descripción completa

Detalles Bibliográficos
Autores principales: Albach, Fredrik N., Wagner, Frank, Hüser, Andreas, Igel, Julia, Joseph, David, Hilbert, James, Schoelch, Corinna, Padula, Steven J., Steffgen, Jürgen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765193/
https://www.ncbi.nlm.nih.gov/pubmed/29127458
http://dx.doi.org/10.1007/s00228-017-2362-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5765193/
https://www.ncbi.nlm.nih.gov/pubmed/29127458
http://dx.doi.org/10.1007/s00228-017-2362-8

Ejemplares similares